Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants. A three-year clinical trial led by University of ...

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention ...

Share on Pinterest New research indicates a drug used to treat type 2 diabetes may help lower the risk of dementia. Fertnig/Getty Images Researchers are saying the drug pioglitazone may help reduce ...

WEDNESDAY, March 30, 2016 -- More evidence linking the diabetes drug Actos to an increased risk of bladder cancer has surfaced in a new study that also finds the risk rises with increased use. Actos ...

Actos (pioglitazone) is a prescription drug that’s used to treat type 2 diabetes. This drug can interact with other medications and some supplements. For example, Actos can interact with certain other ...

The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of ...

"Whether these differences in lipid effects translate into differences in the risk of cardiovascular disease has yet to be determined," lead author Dr Ronald B Goldberg (University of Miami School of ...

Since studies of the diabetes drug Actos suggest an increased risk of bladder cancer for patients taking it for more than a year, Health Canada is reviewing the drug. The drug pioglitazone is sold ...

Please provide your email address to receive an email when new articles are posted on . Patients taking pioglitazone for type 2 diabetes demonstrated an increased risk for bladder cancer, according to ...

San Diego, CA, June 11, 2005 - A new study presented today at the American Diabetes Association (ADA) 65th Annual Scientific Sessions showed that the type 2 diabetes drug ACTOS reduced C-reactive ...

* Better blood sugar lowering, weight loss with exenatide * 66 pct reach A1C target, vs 56 for Actos, 42 for Januvia By Bill Berkrot NEW YORK, June 6 (Reuters) - The high-profile experimental ...